clinical trial · NCT03939533
Study to Monitor Subcutaneous Human Immunoglobulin Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency Diseases
Octapharma·phase3·completed·n = 64
Primary Immune Deficiency DisorderCUTAQUIG
brief summary
CLINICAL PHASE 3 STUDY TO MONITOR THE SAFETY, TOLERABILITY, AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (CUTAQUIG®) ADMINISTERED AT MODIFIED DOSING REGIMENS IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES
started
Oct 17, 2019
primary completion
Jan 3, 2022
completion
Jan 3, 2022
last updated
Nov 7, 2023
official title
Clinical Phase 3 Study to Monitor the Safety, Tolerability, and Efficacy of Subcutaneous Human Immunoglobulin (CUTAQUIG®) Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency Diseases
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol